Copy of `Vernalis - Bio-pharmaceutical glossary`
The wordlist doesn't exist anymore, or, the website doesn't exist anymore. On this page you can find a copy of the original information. The information may have been taken offline because it is outdated.
|
|
Vernalis - Bio-pharmaceutical glossary
Category: Health and Medicine > pharmaceutical
Date & country: 11/12/2007, UK Words: 111
|
Substantia NigraA group of nerve cell bodies in the mid-brain that contain dopamine. It is this part of the brain that degenerates in Parkinson's disease. The levels of the neurotransmitter dopamine are unusually low in Parkinson's patients. Replacement of dopamine is one strategy to relieve symptoms.
SynthesisThe preparation of a substance by chemical means as opposed to its extraction from a natural source.
ToxicCausing an undesired or adverse effect. Most substances will cause adverse effects if high enough doses are given.
ToxicologyThe study of the undesired or adverse effects of a substance on the body.
TriptanAll marketed drugs have an internationally approved name for the compound (drug substance), as distinct from the trade name. The system of naming employs a common “stem� for each member of a class of compounds sharing the same mechanism of action. “Triptan� (as in frovatriptan) is the stem adopted for drugs that act on 5-HT1 receptors and which share a similar mechanism of action in relieving migraine attacks.
VasoconstrictionAn induced narrowing of blood vessels.
VasodilationAn induced expansion of blood vessels.
VasospasmProlonged and profound constriction of blood vessels leading to inadequate blood supply to a tissue or organ.
White MatterAreas of the brain rich in axons. The white appearance occurs due to the high density of myelin, the fatty insulation which covers the axons (like insulation on electrical cable).
XanthineA molecular structure found in many common drugs and products (eg caffeine).
A2AA subtype of adenosine receptor which is believed to be important in Parkinson's disease, depression and anxiety.